David Mazzo

David J.
Mazzo currently works at Lisata Therapeutics, Inc., as President, Chief Executive Officer & Director from 2017, Feldan Bio, Inc., as Chairman from 2023, American Association of Pharmaceutical Scientists, as Member, AOAC International, as Member, and Bonnie Brae, Inc., as Trustee from 2010.
Dr. Mazzo also formerly worked at Æterna Zentaris, Inc., as President, CEO & Executive Director from 2007 to 2008, Regado Biosciences, Inc., as Chief Executive Officer & Executive Director from 2013 to 2014, Caladrius Biosciences, Inc., as Chief Executive Officer & Director from 2015 to 2017, Chugai Pharma USA LLC, as President, CEO & Executive Director from 2003 to 2007, Essex Chimie AG, as Chief Executive Officer & Director, Visioneering Technologies, Inc., as Chairman from 2020 to 2024, Schering-Plough Corp., as Director, Avanir Pharmaceuticals, Inc., as Independent Director from 2011 to 2015, Rhone-Poulenc Rorer, Inc., as Senior Director from 1991 to 1997, EyePoint Pharmaceuticals, Inc., as Independent Non-Executive Director from 2018 to 2020, Seneca Biopharma, Inc., as Independent Director from 2019 to 2021, Hoechst Marion Roussel, Inc., as Director, Essex SAS, as Director, Hoechst Marion Roussel Ltd. (United Kingdom), as SVP-Global Head Pharmaceutical Development, Roche Group, as Member, and Schering-Plough Research Institute, as Senior Vice President-Development Operations from 1998 to 2002.
Dr. Mazzo received his graduate degree and doctorate degree from the University of Massachusetts and undergraduate degree in 1979 from Villanova University.